key: cord-0736731-n99mfy4w authors: Aojula, Nivaran; Ready, Andrew; Gittoes, Neil; Hassan-Smith, Zaki title: Management of Parathyroid Disease during the COVID-19 Pandemic date: 2021-02-26 journal: J Clin Med DOI: 10.3390/jcm10050920 sha: f759d3ae7d21ff68f52b69f436b0a084ed6f7f2f doc_id: 736731 cord_uid: n99mfy4w The coronavirus disease, COVID-19, has caused widespread and sustained disruption to healthcare, not only in the delivery of emergency care, but knock-on consequences have resulted in major delays to the delivery of elective care, including surgery. COVID-19 has accelerated novel pathways for delivering clinical services, many of which have an increased reliance on technology. COVID-19 has impacted care for patients with both hypoparathyroidism and hyperparathyroidism. The role of vitamin D in the prevention of severe COVID-19 infection has also been widely debated. Severe hypocalcemia can be precipitated by infection in patients with hypoparathyroidism. With this in mind, compliance with medical management, including calcium and vitamin D supplementation, is crucial. Technology in the form of text message reminders and smartphone apps may have a key role in ensuring this. Furthermore, clinicians should ensure that patients are educated on the symptoms of hypocalcemia and the steps needing to be taken should these symptoms be experienced. Patients with primary hyperparathyroidism (PHPT) should be educated on the symptoms of hypercalcemia, as well as the importance of remaining adequately hydrated. In addition, patients should be reassured that the postponement of parathyroidectomy is likely to have negligible impact on their condition; for those with symptomatic hypercalcemia, cinacalcet can be considered as an interim measure. The coronavirus disease, COVID-19, has placed a significant burden upon healthcare systems globally. As part of efforts to treat those most adversely affected by COVID-19, services offered by healthcare systems have had to adapt rapidly. Medical and nursing staff have been redeployed from endocrine care to other specialties such as intensive care, which have been placed under greater strain due to rising numbers of acutely unwell patients. Elective surgical procedures and outpatient appointments have been postponed to accommodate rising emergency admissions [1, 2] . The usual management of parathyroid disease during the COVID-19 pandemic has inevitably been disrupted. With the surfacing of new coronavirus variants in the United Kingdom and South Africa [3, 4] , the likelihood of a return to "business as usual" appears unlikely for the foreseeable future. Therefore, it is crucial to implement lessons learnt from the first waves of the pandemic to optimize patient care going forward. This review synthesizes the latest evidence on the impact of COVID-19 on patients with parathyroid disease as well as highlights pragmatic approaches that clinicians could consider in the management of parathyroid disease during the COVID-19 pandemic. It is important to note that this is a narrative review and largely represents specialist consensus as there are limited high-quality studies in this area at this stage. The existing evidence reveals no link suggestive of patients with hypoparathyroidism being more likely to contract the SARS-CoV-2 virus or have worse outcomes. However, there are factors associated with hypoparathyroidism, which have been shown to increase the likelihood of infection. Parathyroid hormone (PTH) plays a key role in the conversion of 25-hydroxyvitamin D to its active form. Individuals with hypoparathyroidism (lacking PTH) have reduced conversion of vitamin D precursors to their active forms; supplementation with active vitamin D is central to the management of the condition [5] . It should be noted that there is evidence of extra-renal hydroxylation of vitamin D. A systematic review and meta-analysis by Martineau et al. of 25 randomized controlled trials (RCTs) concluded that vitamin D supplementation lowered the risk of acute respiratory tract infection [6] . However, previous meta-analyses have reported conflicting results [7, 8] . Furthermore, a previous systematic review noted that whilst observational studies generally showed associations between vitamin D status and risk of respiratory tract infections, data from RCTs showed mixed results [9] . More recently, a review by Grant et al. suggested that high-dose vitamin D supplementation may help lower the risk of contracting certain viral respiratory tract infections [10] ; however, at present, there is insufficient evidence to support this claim for COVID-19 due to a lack of RCT data in this area. In the UK, a rapid evidence review was performed by the National Institute for Health and Care Excellence (NICE) and the Scientific Advisory Committee on Nutrition (SACN), and a pragmatic approach has been taken where vitamin D supplementation (at a dose of 400 IU/day (10 mcg)) should be considered in the winter months for those at risk of vitamin D deficiency [11] . There are high rates of vitamin D deficiency in the UK population, and such dosing is unlikely to cause harm, although it is likely that this dose would not be sufficient for some patients, particularly those with confirmed vitamin D deficiency on a standard dose induction regimen (such as 3200 IU/day (80 mcg) colecalciferol or equivalent, for 6 weeks) followed by maintenance supplementation (such as colecalciferol 800 to 1000 IU/day (20-25 mcg) or equivalent). In parathyroid disease, it is vital that patients are educated on the importance of medication adherence, especially during the COVID-19 pandemic. Technology can be utilized to ensure compliance, either through telephone or text reminders [12] , or alternatively, patients can be directed toward smartphone medication adherence apps. Moreover, clear communication between primary and secondary care clinicians is fundamental to ensuring a continual supply of prescribed medications for patients [12] . Generally, avoidance of clinically apparent hypocalcemia is a central treatment aim in the management of hypoparathyroidism [12] . Historically, it is known that viral infections can precipitate hypocalcemia [13] [14] [15] . Singh et al. have highlighted the underlying mechanisms behind severe COVID-19 infection and hypocalcemia [16] . Patients severely affected by COVID-19 have higher levels of unbound [17] and unsaturated fatty acids [18] . The high levels of unsaturated fatty acids can precipitate a cytokine storm [19] and also bind calcium, leading to reduced calcium levels [20] . Furthermore, another study has suggested that lower levels of vitamin D may be associated with more severe COVID infection and therefore a greater likelihood of hypocalcemia [21] . Hypocalcemia has been commonly observed amongst COVID-19 patients. Filippo et al. in their retrospective cohort study of 531 COVID-19 patients admitted to the Emergency Department of San Raffaele Hospital in Milan found that between 78.6 and 82.0% of patients were hypocalcemic, with this being severe in 1.9% of patients [22] . Furthermore, hypocalcemia was found to be a significant predictor of hospitalization with an odds ratio of 4.15 (2.21-7.78, p < 0.001). Hypocalcemia was also associated with more severe infection and was predictive of Intensive Care Unit (ICU) admission and death in univariate but not multivariate analyses [22] . This finding of lower calcium levels being associated with more adverse outcomes has been reiterated by two other studies [23, 24] . However, it is important to note that this relationship may be more of an association rather than causal. For example, patients who are more ill may present with greater electrolyte derangement such as hypocalcemia and as a result have poorer outcomes, as opposed to hypocalcemia being a specific causal factor for a poorer outcome. Standard therapy for chronic hypoparathyroidism consists of calcium and active vitamin D supplementation (such as alfacalcidol or calcitriol), and some specialists also use "native" vitamin D (such as colecalciferol or ergocalciferol). The goals of chronic management stated in international guidelines include the following: (i) to prevent clinical features of hypocalcemia, (ii) to maintain serum calcium in the low normal range, (iii) to keep the calcium-phosphate levels at target (below 55 mg 2 /dL 2 which is 4.4 mmol 2 /L 2 ), (iv) to avoid hypercalciuria, (v) to avoid hypercalcemia, and (vi) to avoid renal or extraskeletal calcification [25] . In the case of suspected or confirmed SARS-CoV-2 infection, it is important that patients with hypoparathyroidism continue to comply with vitamin D and calcium supplementation to minimize risk of hypocalcemia. General management principles during the pandemic are listed in Table 1 . Patients who take "native" vitamin D should also continue. Patient awareness of symptoms of hypocalcemia, including muscle cramps and paresthesia, is vital so that patients can take additional calcium supplementation (500-1000 mg), in addition to increasing intake of calcium abundant food and drink such as milk. Empirical changes in alfacalcidol are not generally advised and should be guided by the patient's specialist physician or endocrinologist. Patients should also be made aware of symptoms that may be indicative of hypercalcemia, such as having increased thirst, passing more urine than normal, fatigue, and lethargy. However, if symptoms persist, patients should be aware of the relevant pathways for accessing urgent medical advice [12] . Acute hypocalcemia requiring hospital admission should be managed in line with existing national/international guidelines [25, 26] . This can occur as an early complication of anterior neck surgery or in patients who are not compliant with calcium/vitamin D supplementation or as a complication of malabsorption. Symptoms include muscle cramps, paresthesia, and carpopedal spasm. Treatment with intravenous (IV) calcium is indicated in acute symptomatic cases (international guidelines advise the use of 1-2 ampoules of 10% calcium gluconate containing 90-180 mg elemental calcium in 50 mL of 5% dextrose over 10-20 min followed by a slower infusion of calcium gluconate 0.5-1.5 mg/kg/h over 8-10 h) before initiating dose titration of oral calcium supplements and vitamin D analogues [25] . [12] . Patient education on the symptoms of hypocalcemia and hypercalcemia. Paresthesia and muscle cramps may be indicative of hypocalcemia. Increased thirst, polyuria, nocturia, and lethargy may indicate that over-treatment has resulted in hypercalcemia. Patients should be made aware of appropriate next steps should symptoms develop Emphasizing the importance of adherence to prescription medication to patients (utilizing text message reminders or encouraging the use of medication adherence smartphone applications) Informing patients of the need to seek medical advice should diarrhea or vomiting develop, as medication doses may need to be altered. Other recognized symptoms associated with SARS-CoV-2 infection are diarrhea and vomiting [27] . Should patients experience diarrhea and vomiting, they should seek medical advice urgently due to the possibility of poor absorption and need for medication doses to be altered [12] . Evidence for this is lacking; however, an interesting case was reported by Elkattawy et al., where SARS-CoV-2 infection as the cause for hypoparathyroidism was suspected. The authors report the case of a 46-year-old male patient with an unremarkable medical history, following admission for hypoxic respiratory failure secondary to SARS-CoV-2 infection. Other well-established causes of hypoparathyroidism such as genetic causes or malignancy were excluded [28] . Given that this is a case report, limited conclusions can be drawn from it; however, it does suggest the need for further investigation in this field to identify if there is any link between SARS-CoV-2 infection and parathyroid function. Primary hyperparathyroidism (PHPT) is a common condition characterized by inappropriately raised PTH secretion, which may result in hypercalcemia and associated symptoms [29] . PHPT has a slow onset, with many patients being unaware of the presence of the condition until symptoms of hypercalcemia develop. Due to the slow-evolving nature of the condition, diagnostic investigations for localizing the disease and determining the end-organ impact of the disease, such as on bone mineral density and renal function (including nephrolithiasis) should be delayed if necessary regarding the COVID-19 pandemic context [12] . Patients with PHPT should be reminded of the symptoms of hypercalcemia such as vomiting, nausea, and abdominal pain. This can be achieved by directing patients to reliable sources of online information such as the UK National Health Service (NHS) website, where information is displayed in a simple and understandable format. In addition, patients should be informed about the importance of staying hydrated, given that dehydration can precipitate hypercalcemia [12] . SARS-CoV-2 infection is associated with symptoms such as a fever, diarrhea, and vomiting [25] , all contributing to dehydration. Therefore, it is vital that patients remain well-hydrated should such symptoms develop. Failure to achieve adequate hydration may amount in a deterioration of their condition and progressive hypercalcemia, which may demand emergency admission [12] . A summary of key priorities for managing PHPT during the pandemic is provided in Table 2 . Table 2 . A summary of the key priorities for managing primary hyperparathyroidism (PHPT) during the COVID-19 pandemic [12] . Patient education on the symptoms of hypercalcemia such as abdominal pain, nausea, and vomiting and informing patients of the appropriate next steps should symptoms of hypercalcemia develop Emphasizing the importance of remaining adequately hydrated Explain to patients who have had their parathyroidectomy postponed that their condition is unlikely to deteriorate, as PHPT is a slow-evolving condition Consider cinacalcet to manage symptomatic hypercalcemia Some international guidelines and consensus statements [30, 31] that were written prior to the emergence of COVID-19 outline the following indications for surgery in asymptomatic patients for the treatment of PHPT: (1) age < 50 years; (2) serum calcium > 1 mg/dL or > 0.25 mmol/L of the upper limit of the reference range; (3) Bone Mineral Density (BMD) T-score of